close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alterome Therapeutics, Inc.

News headline image
Alterome Therapeutics to Participate in November Investor Conferences
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics to Present First Clinical Data from Phase 1/1b Trial of ALTA3263 in KRAS-Mutant Advanced Solid Tumors in Late-Breaking Presentation at the 38th EORTC-NCI-AACR Symposium
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Appoints Johanna Mylet as Chief Financial Officer
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics to Participate in Upcoming Investor Conferences
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics to Participate in Upcoming Investor Conferences
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Eric Murphy, Ph.D., Co-Founder and CEO of Alterome, Named to Goldman Sachs Top 100 Most Exceptional Entrepreneurs at 2024 Builders and Innovators Summit
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies
From Alterome Therapeutics, Inc.
Via Business Wire
News headline image
Alterome Therapeutics Launches With $64M Series A Financing
From Alterome Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.